The global slowdown in clinical trials for new COVID-19 vaccines raises questions that extend far beyond the medical field, touching upon the core pillars of human rights and bioethics. As science evolves to address an endemic virus, international institutions have a duty to ensure that this transition does not occur at the expense of transparency and freedom of choice.

The Right to Transparency and Informed Consent

Recent difficulties in recruiting volunteers for clinical trials reflect a shift in collective awareness. From a human rights perspective, informed consent (as outlined in Article 3 of the EU Charter of Fundamental Rights and the Nuremberg Code) remains the cornerstone of medical experimentation.

• The Value of Participation: The shortage of participants is not merely a logistical hurdle; it is a signal from a population demanding greater clarity regarding long-term risks and benefits, particularly in a context where a state of emergency no longer justifies accelerated procedures.

• Self-Determination: The challenges faced by pharmaceutical companies highlight the importance of an individual’s right to refuse medical treatment without coercion, emphasizing that participation must be voluntary and based on indisputable evidence.

Regulatory Evolution and Citizen Protection

The debate over transitioning to an approval model similar to that of the seasonal flu vaccine—potentially bypassing large-scale Phase 3 trials for every update—raises concerns regarding the right to health and safety.

• Balancing Efficacy and Oversight: If regulatory authorities (such as the EMA or FDA) reduce sampling requirements to expedite drug access, it is imperative that active pharmacovigilance mechanisms are strengthened. The right to health implies not only access to treatment but the guarantee that such treatments are monitored with the utmost rigor.

• International Treaties: Any modification to experimental protocols must remain aligned with the principles of the Declaration of Helsinki, which mandates that the well-being of the individual subject must always take precedence over the interests of science or society.

Discrimination and Equitable Access

A human rights-based analysis must also address the risk of market consolidation. As public funding wanes and many independent research projects are abandoned, the landscape is increasingly dominated by a few global entities.

• The Right to Information: It is essential that citizens are not deprived of accurate scientific information due to commercial interests. Freedom of opinion and expression must be protected within the critical debate on vaccination policies, ensuring that informed dissent is not suppressed.

Conclusion: Toward an Ethical Research Model

The end of the emergency phase of large-scale clinical trials presents an opportunity to return human dignity to the center of the discourse. The challenge for the future is not only to produce effective medicine but to rebuild the bond of trust between citizens, institutions, and the scientific community—a bond founded on the rigorous respect for fundamental rights and data transparency.